Orris

Describe benign and malignant ovarian tumors in detail, write about FIGO staging and management of Carcinoma Ovary 30 marks question in PG Obs and gynec

Reading File
Finding Sources
Finding Sources
Searching Images

ovarian tumor classification benign malignant

This diagnostic image display illustrates occlusion analysis results for deep learning classification of ovarian tumors using CT scan data. The visual is divided into two main sections: (a) Benign and (b) Malignant. For each category, axial CT slices of the pelvis are shown alongside corresponding heatmaps. In the benign samples, the original CT scans depict large, well-circumscribed, homogeneous masses within the adnexal region. The associated occlusion heatmaps show concentrated, high-intensity (bright) regions localized strictly within the tumor boundaries, indicating specific structural features the model uses for benign classification. Conversely, the malignant samples show smaller, more irregularly shaped pelvic masses. The corresponding heatmaps for malignant cases display a more diffuse, scattered, and lower-intensity spatial distribution of 'important' pixels, suggesting that the model relies on broader, less-defined morphological features for malignant identification. This comparison highlights the use of explainable AI (XAI) techniques in gynecologic oncology to visualize the decision-making process of neural networks (ResNet60) in distinguishing between benign and malignant ovarian neoplasms based on texture and spatial characteristics.

This diagnostic image display illustrates occlusion analysis results for deep learning classification of ovarian tumors using CT scan data. The visual is divided into two main sections: (a) Benign and (b) Malignant. For each category, axial CT slices of the pelvis are shown alongside corresponding heatmaps. In the benign samples, the original CT scans depict large, well-circumscribed, homogeneous masses within the adnexal region. The associated occlusion heatmaps show concentrated, high-intensity (bright) regions localized strictly within the tumor boundaries, indicating specific structural features the model uses for benign classification. Conversely, the malignant samples show smaller, more irregularly shaped pelvic masses. The corresponding heatmaps for malignant cases display a more diffuse, scattered, and lower-intensity spatial distribution of 'important' pixels, suggesting that the model relies on broader, less-defined morphological features for malignant identification. This comparison highlights the use of explainable AI (XAI) techniques in gynecologic oncology to visualize the decision-making process of neural networks (ResNet60) in distinguishing between benign and malignant ovarian neoplasms based on texture and spatial characteristics.

A diagnostic imaging comparison featuring Grad-CAM (Gradient-weighted Class Activation Mapping) results for benign and malignant ovarian tumor classification using axial CT scans. The figure is divided into two sections: (a) Benign and (b) Malignant samples. Each section displays three columns: the original cropped CT image with manual annotation outlines, the standalone Grad-CAM heatmap, and the heatmap overlaid on the CT image. The benign samples demonstrate tumors with relatively smooth, well-defined boundaries and more homogeneous internal textures; the corresponding Grad-CAM heatmaps show concentrated, localized activation areas. In contrast, the malignant samples display tumors with irregular shapes and less distinct margins. The Grad-CAM heatmaps for the malignant class show broader, more dispersed activation regions that extend into the surrounding pelvic tissue, suggesting the model utilizes features of potential local spread or invasion for classification. This comparison illustrates how deep learning interpretability tools identify morphological and peri-tumoral characteristics used to differentiate tumor types in gynecological oncology.

A diagnostic imaging comparison featuring Grad-CAM (Gradient-weighted Class Activation Mapping) results for benign and malignant ovarian tumor classification using axial CT scans. The figure is divided into two sections: (a) Benign and (b) Malignant samples. Each section displays three columns: the original cropped CT image with manual annotation outlines, the standalone Grad-CAM heatmap, and the heatmap overlaid on the CT image. The benign samples demonstrate tumors with relatively smooth, well-defined boundaries and more homogeneous internal textures; the corresponding Grad-CAM heatmaps show concentrated, localized activation areas. In contrast, the malignant samples display tumors with irregular shapes and less distinct margins. The Grad-CAM heatmaps for the malignant class show broader, more dispersed activation regions that extend into the surrounding pelvic tissue, suggesting the model utilizes features of potential local spread or invasion for classification. This comparison illustrates how deep learning interpretability tools identify morphological and peri-tumoral characteristics used to differentiate tumor types in gynecological oncology.

A comparative collection of ten transvaginal ultrasound (TVU) scan images illustrating the diagnostic features of benign (B1–B5) and malignant (M1–M5) ovarian masses, structured according to the International Ovarian Tumor Analysis (IOTA) simple rules. The benign series (B panels) demonstrates markers of low malignancy risk: B1 shows a simple unilocular cyst; B2 shows small solid components (<7 mm); B3 exhibits acoustic shadowing; B4 displays a smooth multilocular cyst (<100 mm); and B5 shows a lack of vascularity (color score 1). The malignant series (M panels) highlights predictive features for ovarian cancer: M1 identifies an irregular solid tumor; M2 shows adnexal masses with associated ascites; M3 demonstrates multiple papillary projections (at least four); M4 identifies a large irregular multilocular solid tumor (≥100 mm); and M5 displays intense internal neoangiogenesis (color score 4) via color Doppler imaging. This clinical resource serves as an educational guide for sonographic risk stratification of adnexal masses in gynecology and oncology.

A comparative collection of ten transvaginal ultrasound (TVU) scan images illustrating the diagnostic features of benign (B1–B5) and malignant (M1–M5) ovarian masses, structured according to the International Ovarian Tumor Analysis (IOTA) simple rules. The benign series (B panels) demonstrates markers of low malignancy risk: B1 shows a simple unilocular cyst; B2 shows small solid components (<7 mm); B3 exhibits acoustic shadowing; B4 displays a smooth multilocular cyst (<100 mm); and B5 shows a lack of vascularity (color score 1). The malignant series (M panels) highlights predictive features for ovarian cancer: M1 identifies an irregular solid tumor; M2 shows adnexal masses with associated ascites; M3 demonstrates multiple papillary projections (at least four); M4 identifies a large irregular multilocular solid tumor (≥100 mm); and M5 displays intense internal neoangiogenesis (color score 4) via color Doppler imaging. This clinical resource serves as an educational guide for sonographic risk stratification of adnexal masses in gynecology and oncology.

This diagnostic imaging graphic is a categorized collection of ultrasound images of adnexal masses, organized for differential diagnosis. The top tier distinguishes masses by malignancy potential: 'Borderline' and 'Malignant' images use color Doppler flow imaging, demonstrating varying degrees of vascularity and solid components within the ovarian structures. The bottom tier provides a pathological subtype classification of benign masses. 'Endometriomas' show characteristic low-level internal echoes (ground-glass appearance). 'Other epithelial tumors' appear as clear, anechoic cystic structures. 'Germ cell tumors' and 'Sex cord stromal tumors' exhibit more complex, heterogeneous echogenicity. The 'Inflammation' image shows a multiloculated, ill-defined mass consistent with a tubo-ovarian abscess or similar inflammatory process. The content serves as an educational tool for identifying sonographic features—such as echogenicity, septations, solid areas, and blood flow—used in the IOTA (International Ovarian Tumor Analysis) framework to classify ovarian pathology.

This diagnostic imaging graphic is a categorized collection of ultrasound images of adnexal masses, organized for differential diagnosis. The top tier distinguishes masses by malignancy potential: 'Borderline' and 'Malignant' images use color Doppler flow imaging, demonstrating varying degrees of vascularity and solid components within the ovarian structures. The bottom tier provides a pathological subtype classification of benign masses. 'Endometriomas' show characteristic low-level internal echoes (ground-glass appearance). 'Other epithelial tumors' appear as clear, anechoic cystic structures. 'Germ cell tumors' and 'Sex cord stromal tumors' exhibit more complex, heterogeneous echogenicity. The 'Inflammation' image shows a multiloculated, ill-defined mass consistent with a tubo-ovarian abscess or similar inflammatory process. The content serves as an educational tool for identifying sonographic features—such as echogenicity, septations, solid areas, and blood flow—used in the IOTA (International Ovarian Tumor Analysis) framework to classify ovarian pathology.

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images

FIGO staging ovarian cancer diagram

This medical illustration depicts the FIGO staging system for ovarian cancer, using a series of anatomical diagrams to show disease progression. Stage I focuses on the reproductive organs: Stage IA shows a tumor limited to one ovary or fallopian tube, while Stage IB involves both. Stage IC subtypes (IC1-IC3) illustrate intraoperative spill and malignant cells in ascites. Stage II diagrams depict pelvic extension, with IIA showing involvement of the uterus and IIB showing further pelvic spread. Stage III focuses on extrapelvic peritoneal involvement and lymph node metastasis: IIIA1 highlights positive retroperitoneal lymph nodes, IIIA2 shows microscopic extrapelvic peritoneal involvement, and IIIB/IIIC represent macroscopic peritoneal metastasis (distinguished by size thresholds of 2 cm). Stage IV illustrates distant metastasis: IVA shows pleural effusion with positive cytology (indicated by green fluid around the lungs), and IVB demonstrates parenchymal metastasis to the liver and spleen and extra-abdominal organs. The illustrations utilize sagittal and coronal views of the female pelvis and full torso to highlight clinical landmarks relevant to gynecologic oncology.

This medical illustration depicts the FIGO staging system for ovarian cancer, using a series of anatomical diagrams to show disease progression. Stage I focuses on the reproductive organs: Stage IA shows a tumor limited to one ovary or fallopian tube, while Stage IB involves both. Stage IC subtypes (IC1-IC3) illustrate intraoperative spill and malignant cells in ascites. Stage II diagrams depict pelvic extension, with IIA showing involvement of the uterus and IIB showing further pelvic spread. Stage III focuses on extrapelvic peritoneal involvement and lymph node metastasis: IIIA1 highlights positive retroperitoneal lymph nodes, IIIA2 shows microscopic extrapelvic peritoneal involvement, and IIIB/IIIC represent macroscopic peritoneal metastasis (distinguished by size thresholds of 2 cm). Stage IV illustrates distant metastasis: IVA shows pleural effusion with positive cytology (indicated by green fluid around the lungs), and IVB demonstrates parenchymal metastasis to the liver and spleen and extra-abdominal organs. The illustrations utilize sagittal and coronal views of the female pelvis and full torso to highlight clinical landmarks relevant to gynecologic oncology.

Two side-by-side axial contrast-enhanced CT scans (A and B) of the lower thorax/upper abdomen in a patient with FIGO stage IIIC ovarian cancer, focusing on cardiophrenic lymph node (CPLN) progression. Image A displays the initial staging scan showing a cardiophrenic lymph node (indicated by a red arrow) measuring 6.4 mm in the short axis. Image B shows a follow-up scan of the same anatomical level five months later, where the CPLN has increased in size to 11.3 mm in the short axis. Key visible structures include the heart located centrally, the liver in the right upper quadrant, and the vertebral body posteriorly. The images highlight a specific clinical scenario where CPLN enlargement occurs during the course of advanced ovarian cancer treatment. The pedagogical focus is on recognizing lymphadenopathy in the cardiophrenic space as a potential site for extra-abdominal disease involvement or progression.

Two side-by-side axial contrast-enhanced CT scans (A and B) of the lower thorax/upper abdomen in a patient with FIGO stage IIIC ovarian cancer, focusing on cardiophrenic lymph node (CPLN) progression. Image A displays the initial staging scan showing a cardiophrenic lymph node (indicated by a red arrow) measuring 6.4 mm in the short axis. Image B shows a follow-up scan of the same anatomical level five months later, where the CPLN has increased in size to 11.3 mm in the short axis. Key visible structures include the heart located centrally, the liver in the right upper quadrant, and the vertebral body posteriorly. The images highlight a specific clinical scenario where CPLN enlargement occurs during the course of advanced ovarian cancer treatment. The pedagogical focus is on recognizing lymphadenopathy in the cardiophrenic space as a potential site for extra-abdominal disease involvement or progression.

A multi-panel medical illustration and anatomical diagram depicting the FIGO staging of cervical cancer (Stages IA and IB). The central bottom panel displays a 3D-style anatomical diagram representing Stages IA1 and IA2, where the cervix appears macroscopically normal, indicating microinvasive disease that is not visible to the naked eye. The top left panel illustrates Stage IB1, showing a cross-section of the uterus and cervix with a small, localized dark lesion on the cervical canal; it is annotated as a cancer of 4 mm or smaller. The top right panel illustrates Stage IB2, showing a significantly larger, darker, and more prominent exophytic/ulcerative lesion on the cervix, annotated as being larger than 4 cm. All panels show relevant reproductive anatomy including the uterus, fallopian tubes, and ovaries. This educational graphic serves to distinguish clinical stages of cervical carcinoma based on tumor size and macroscopic visibility, relevant for gynecologic oncology and diagnostic pathology training.

A multi-panel medical illustration and anatomical diagram depicting the FIGO staging of cervical cancer (Stages IA and IB). The central bottom panel displays a 3D-style anatomical diagram representing Stages IA1 and IA2, where the cervix appears macroscopically normal, indicating microinvasive disease that is not visible to the naked eye. The top left panel illustrates Stage IB1, showing a cross-section of the uterus and cervix with a small, localized dark lesion on the cervical canal; it is annotated as a cancer of 4 mm or smaller. The top right panel illustrates Stage IB2, showing a significantly larger, darker, and more prominent exophytic/ulcerative lesion on the cervix, annotated as being larger than 4 cm. All panels show relevant reproductive anatomy including the uterus, fallopian tubes, and ovaries. This educational graphic serves to distinguish clinical stages of cervical carcinoma based on tumor size and macroscopic visibility, relevant for gynecologic oncology and diagnostic pathology training.

Reading File
Reading File
I now have all the material needed. Let me write the comprehensive answer.

Ovarian Tumors: Benign, Malignant, FIGO Staging, and Management of Carcinoma Ovary

(30 Marks - PG Obs & Gynec Answer)

INTRODUCTION

The ovary is a unique structure in that it gives rise to a wider variety of tumors than any other organ in the body. This diversity stems from the three fundamental cell populations in the ovary:
  1. Müllerian (coelomic) epithelium - surface epithelial-stromal tumors (65-70%)
  2. Germ cells - germ cell tumors (15-20%)
  3. Sex cord-stromal cells - sex cord-stromal tumors (5-10%)

CLASSIFICATION OF OVARIAN TUMORS

WHO Classification (Histological - Table 1)

CategoryCell of OriginMajor Types
Epithelial-StromalMüllerian/coelomic epitheliumSerous, Mucinous, Endometrioid, Clear cell, Brenner, Mixed
Germ CellPrimordial germ cellsTeratoma, Dysgerminoma, Yolk sac tumor, Choriocarcinoma
Sex Cord-StromalGonadal mesenchymeGranulosa cell, Theca cell, Sertoli-Leydig cell tumors
Secondary (Metastatic)Various primary sitesKrukenberg tumor (from stomach/colon)
Each epithelial type is further subdivided into:
  • Benign (well-differentiated, minimal proliferation, no invasion)
  • Borderline (low malignant potential - increased proliferation but no stromal invasion)
  • Malignant (stromal invasion present, cytological atypia)

PART I: BENIGN OVARIAN TUMORS

A. Benign Epithelial Tumors

1. Serous Cystadenoma

  • Commonest benign ovarian tumor (25% of all benign)
  • Gross: Unilocular/multilocular cyst, smooth outer surface, thin wall, straw-colored watery fluid
  • Histology: Single layer of ciliated tubal-type columnar epithelium (salpingeal type); psammoma bodies (concentric calcifications) may be seen
  • Size: Usually 5-15 cm; bilateral in ~15%
  • Papillary excrescences on inner wall may be present; outer surface excrescences suggest malignant transformation

2. Mucinous Cystadenoma

  • Second most common benign ovarian neoplasm (8-10% of epithelial tumors)
  • Gross: Multilocular, huge - can fill entire abdominal cavity; mucoid gelatinous content
  • Histology: Tall columnar mucin-secreting epithelium resembling endocervix or intestinal goblet cells; intracytoplasmic mucin
  • Bilateral: Only 2-5%
  • Complication: Rupture can cause pseudomyxoma peritonei - mucinous material throughout peritoneal cavity
Pseudomyxoma peritonei: The peritoneal cavity fills with gelatinous mucin surrounded by fibrous tissue. Most commonly it is secondary to a well-differentiated appendiceal mucinous neoplasm. - Berek & Novak's Gynecology

3. Brenner Tumor

  • Rare; composed of transitional (urothelial-type) epithelium within dense fibrous stroma
  • Usually small, solid, unilateral, and incidental finding
  • Cut surface: resembles fibroma
  • Almost always benign; malignant Brenner rare

4. Endometrioid Cystadenoma (Benign)

  • Lined by endometrium-like epithelium; rarely purely benign (most are borderline or in context of endometriosis)

B. Functional/Non-Neoplastic Cysts (Benign)

TypeFeatures
Follicular cystUnruptured Graafian follicle; <8 cm; lined by granulosa cells; resolves spontaneously
Corpus luteal cystPost-ovulation; hemorrhage possible ("chocolate"; may rupture)
Theca-lutein cystsBilateral; seen in molar pregnancy / ovarian hyperstimulation; very elevated hCG
Polycystic ovaryMultiple follicular cysts; associated with androgen excess, anovulation

C. Benign Germ Cell Tumors

Mature Cystic Teratoma (Dermoid Cyst)

  • Most common ovarian tumor in young women (20-30 years)
  • Bilateral in 10-15%
  • Gross: Unilocular cyst; thick sebaceous material, hair, teeth, bone fragments; Rokitansky protuberance (solid area)
  • Histology: Stratified squamous epithelium with sebaceous glands, hair follicles, cartilage, thyroid tissue, neural elements - derivatives of all three germ layers
  • Karyotype: Normal female 46,XX
  • Complications: Torsion (most common), rupture, infection, hemolytic anemia, and malignant transformation (~1% - usually to squamous cell carcinoma)
  • Tumor marker: May show elevated AFP if neural elements present; elevated CA-125 if skin/sebaceous elements rupture
"Occasionally associated with clinically important paraneoplastic syndromes, such as inflammatory limbic encephalitis, which may remit following removal of the tumor." - Robbins Pathology

Struma Ovarii

  • Monodermal teratoma composed predominantly of thyroid tissue
  • May cause hyperthyroidism; rarely malignant

D. Benign Sex Cord-Stromal Tumors

Fibroma

  • Most common benign sex cord-stromal tumor
  • Solid, white-gray, rubbery; produces fibrous tissue
  • Meigs syndrome: Fibroma + ascites + right-sided pleural effusion
  • Treatment: Simple oophorectomy (curative)

Thecoma

  • Rare; contains lipid-laden theca cells; produces estrogen
  • Post-menopausal; associated with endometrial hyperplasia

PART II: MALIGNANT OVARIAN TUMORS (CARCINOMA OVARY)

Epidemiology

  • 3rd most common gynecological malignancy in India (after Ca cervix and Ca endometrium)
  • Leading cause of gynecological cancer death (due to late presentation)
  • Peak incidence: 50-70 years
  • 5-year survival (all stages): ~46%; Stage I: ~90%; Stage IV: <20%

Risk Factors

Increased RiskDecreased Risk
BRCA1/BRCA2 mutationsOCP use
Family history (1st degree)Multiple pregnancies
Nulliparity, early menarche, late menopauseBreastfeeding
Lynch syndrome / HNPCCTubal ligation
HRT (long-term)Salpingectomy / oophorectomy
Talc exposure

A. Epithelial Ovarian Cancer (EOC) - 65-70% of all

Molecular Pathogenesis - Type I vs Type II (Berek & Novak)

FeatureType I (Low-grade)Type II (High-grade)
OriginSerous borderline tumors, endometriosisFallopian tube fimbriae (STIC), inclusion cysts
GrowthSlowRapid
Genetic mutationsKRAS, BRAF, ERBB2TP53 (nearly universal), BRCA1/2
Genetic stabilityStableUnstable (chromosomal)
Stage at diagnosisOften earlyUsually advanced
HistotypesLow-grade serous, mucinous, endometrioidHigh-grade serous, carcinosarcoma

Histological Subtypes of EOC

1. Serous Adenocarcinoma (75-80% of EOC)
  • Two grades: Low-grade (Type I, indolent) and High-grade (Type II, aggressive)
  • High-grade serous is the most lethal; nearly all have TP53 mutations
  • Microscopy: Papillae lined by cytologically malignant cells; necrosis; psammoma bodies
  • Serous tubal intraepithelial carcinoma (STIC): Precursor in fallopian tube fimbria
2. Mucinous Carcinoma (5%)
  • Bilateral in only 8-10%; confined to ovary in 95-98%
  • Must exclude metastasis from GI tract (primary vs. Krukenberg)
  • Microscopy: Irregular glandular spaces lined by tall columnar cells with abundant mucinous cytoplasm
3. Endometrioid Carcinoma (10%)
  • Arises from endometriosis; associated with synchronous endometrial cancer in 15-20%
  • Better prognosis than serous
4. Clear Cell Carcinoma (5%)
  • Müllerian origin; arises from endometriosis
  • High resistance to platinum chemotherapy; worse prognosis
  • Microscopy: "Hobnail" cells, glycogen-rich clear cytoplasm
5. Undifferentiated/Unclassified
  • High grade, poor prognosis; anaplastic cells

B. Malignant Germ Cell Tumors (15-20%)

Predominantly in young girls and adolescents; excellent response to chemotherapy
TumorMarkerFeatures
DysgerminomaLDH, PLAPMost common malignant GCT; equivalent of testicular seminoma; 10-15% bilateral; radiosensitive and chemo-sensitive
Yolk Sac Tumor (Endodermal sinus)AFP (elevated)Schiller-Duval bodies histologically; aggressive; most common in children
Immature TeratomaAFP, CA-125Primitive neuroepithelium; graded 1-3; younger women
Choriocarcinomaβ-hCG (very high)Extremely rare; aggressive; hematogenous spread; may cause precocious puberty
Embryonal carcinomaAFP + β-hCGHighly malignant; mixed patterns

C. Sex Cord-Stromal Tumors (5-10%)

Granulosa Cell Tumor (GCT)

  • Low-grade malignancy; bilateral in <5%
  • Produces estrogen → endometrial hyperplasia/carcinoma (risk)
  • Histology: Call-Exner bodies (rosette pattern around pink material - pathognomonic)
  • Tumor marker: Inhibin, AMH
  • Adult type: Perimenopausal women; late recurrence (10-30 years later)
  • Juvenile type: Children and adolescents; isosexual precocious puberty

Sertoli-Leydig Cell Tumor (Androblastoma)

  • Produces androgens → virilization (amenorrhea, clitoromegaly, voice deepening, hirsutism)
  • Rare; usually in young women <30 years
  • Mostly unilateral; low-grade malignancy

D. Metastatic Tumors (Krukenberg Tumor)

  • Bilateral ovarian metastases (usually from stomach or colon)
  • Histology: Signet-ring cells containing mucin within cellular stroma
  • Poor prognosis

PART III: CLINICAL FEATURES OF CARCINOMA OVARY

Symptoms (Ovarian Cancer Symptom Index)

  • Pelvic or abdominal pain
  • Abdominal bloating/distension
  • Difficulty eating / early satiety
  • Urinary urgency or frequency
  • Increased abdominal girth (ascites)

Signs

  • Pelvic mass: solid, irregular, fixed, bilateral - highly suggestive of malignancy
  • Ascites
  • Upper abdominal mass (omental cake)
  • Pleural effusion (in advanced disease)

Investigation

InvestigationSignificance
CA-125Elevated in 80-90% advanced serous; >200 U/mL in postmenopausal = 96% PPV; less specific premenopausal
Transvaginal USGMorphology assessment; complex mass with solid areas, septae, papillary projections, ascites
CT abdomen-pelvisStaging, nodal assessment, peritoneal deposits
MRI pelvisSuperior soft tissue characterization
AFP, β-hCG, LDHFor germ cell tumors in young women
InhibinGranulosa cell tumors
Chest X-ray/CTPleural effusion (Stage IVA)

PART IV: FIGO STAGING OF OVARIAN CANCER (2014 Revised)

The 2014 FIGO staging applies to ovarian, fallopian tube, and primary peritoneal carcinomas:
FIGO staging ovarian cancer diagram

STAGE I - Tumor confined to ovaries / fallopian tubes

StageDefinition
IAOne ovary/tube; capsule intact; no surface tumor; negative washings
IBBoth ovaries/tubes; capsule intact; no surface tumor; negative washings
IC1Surgical spill intraoperatively
IC2Preoperative capsule rupture OR tumor on ovarian/tubal surface
IC3Malignant cells in ascites or peritoneal washings

STAGE II - Pelvic extension or primary peritoneal cancer

StageDefinition
IIAExtension and/or implants on uterus and/or tubes
IIBExtension to other pelvic intraperitoneal tissues (bladder, sigmoid, rectum)

STAGE III - Peritoneal metastases beyond pelvis AND/OR retroperitoneal lymph node metastases

StageDefinition
IIIA1Positive retroperitoneal lymph nodes only (cytologically/histologically confirmed)
IIIA1(i)Nodal metastasis ≤10 mm in greatest dimension
IIIA1(ii)Nodal metastasis >10 mm in greatest dimension
IIIA2Microscopic extrapelvic (above the pelvic brim) peritoneal involvement ± positive retroperitoneal nodes
IIIBMacroscopic peritoneal metastasis beyond pelvis ≤2 cm ± positive retroperitoneal nodes
IIICMacroscopic peritoneal metastasis beyond pelvis >2 cm ± positive retroperitoneal nodes (including liver/spleen capsule)

STAGE IV - Distant metastases (excluding peritoneal metastases)

StageDefinition
IVAPleural effusion with positive cytology
IVBParenchymal metastases (liver/spleen parenchyma), extra-abdominal organ involvement (including inguinal lymph nodes and lymph nodes outside abdominal cavity)
Key 2014 change: Retroperitoneal lymph node metastasis alone is now Stage IIIA1 (not Stage IIIC) if there is no peritoneal spread beyond the pelvis. Pleural effusion with positive cytology is Stage IVA (not IVB).
5-Year Survival by Stage:
Stage5-Year Survival
I~90%
II~70%
III~39%
IV<20%

PART V: MANAGEMENT OF CARCINOMA OVARY

General Principles

  1. Surgery is the cornerstone - for both diagnosis (histological confirmation) AND treatment (cytoreduction)
  2. Most patients (~75%) present at Stage III/IV
  3. Treatment depends on: Stage, histology, grade, age, performance status, desire for fertility

Surgical Staging Procedure (For Apparently Early Disease)

Performed via vertical midline incision:
  1. Evacuation of ascites / peritoneal washings (diaphragm, right and left paracolic gutters, pelvis)
  2. Total abdominal hysterectomy + bilateral salpingo-oophorectomy (TAH + BSO)
  3. Infragastric omentectomy
  4. Retroperitoneal pelvic and para-aortic lymph node dissection
  5. Appendicectomy (especially for mucinous tumors)
  6. Random biopsies of peritoneal surfaces (diaphragm undersurface, cul-de-sac, paracolic gutters, pelvic side walls, bladder peritoneum)
  7. Excision of all suspicious lesions/adhesions
  • Bailey & Love's Short Practice of Surgery, p.1615

A. Management by Stage

Stage I (Early Disease)

Stage IA/IB Grade 1-2 (Low Risk):
  • TAH + BSO + surgical staging
  • No adjuvant chemotherapy required
  • Fertility-sparing surgery acceptable in young women with Stage IA, Grade 1-2: unilateral salpingo-oophorectomy + staging; uterus and contralateral ovary preserved
Stage IA/IB Grade 3 OR Stage IC (High Risk):
  • TAH + BSO + staging
  • Adjuvant chemotherapy: 3-6 cycles of carboplatin + paclitaxel
Prognostic factors for high risk Stage I: high grade, ruptured capsule, surface excrescences, ascites, positive peritoneal cytology, dense adhesions, aneuploid tumor - Berek & Novak's Gynecology

Stage II

  • TAH + BSO + staging + cytoreduction
  • Adjuvant chemotherapy: 6 cycles of carboplatin (AUC 5-6) + paclitaxel (175 mg/m² IV every 3 weeks)

Stage III-IV (Advanced Disease) - PRIMARY TREATMENT

Cytoreductive Surgery (Debulking Surgery)
The goal is to achieve optimal cytoreduction - residual disease ≤1 cm (ideally no gross residual disease = R0)
Components:
  • TAH + BSO
  • Infragastric omentectomy
  • Peritonectomy
  • Bowel resection if necessary (colorectal resection with reanastomosis)
  • Diaphragmatic resection/stripping
  • Splenectomy and/or distal pancreatectomy if required
"In a meta-analysis of 81 studies, Bristow et al. documented that each 10% increase in cytoreduction equaled a 5.5% increase in median survival." - Berek & Novak's Gynecology
Post-operative Chemotherapy (First Line):
  • Standard IV regimen: Carboplatin AUC 5-6 + Paclitaxel 175 mg/m² IV every 3 weeks x 6 cycles
  • Intraperitoneal (IP) therapy: For optimally debulked Stage III - IP cisplatin/carboplatin + paclitaxel; NCI clinical alert (2006) endorsed IP therapy as superior in survival for optimally cytoreduced patients
  • Dose-dense weekly paclitaxel (80 mg/m² weekly) + carboplatin AUC 5-6 every 3 weeks: superior PFS vs. standard in Japanese trial (JGOG 3016)
Neoadjuvant Chemotherapy (NACT) + Interval Debulking Surgery (IDS):
  • When patient is not a surgical candidate upfront (unresectable disease, poor performance status)
  • Fagotti Score ≥8 at laparoscopy predicts suboptimal cytoreduction → proceed to NACT
  • Protocol: 3 cycles NACT → IDS → 3 cycles adjuvant chemotherapy
  • Supported by EORTC and CHORUS trials (non-inferior to primary debulking for selected patients)
Targeted Therapy:
  • Bevacizumab (anti-VEGF monoclonal antibody):
    • GOG218 and ICON7 trials: Added to 6 cycles CP, then maintenance for 15 months
    • 3.8-month improvement in PFS; no OS benefit except in high-risk subgroup (ascites, Stage IVB)
    • Dose: 7.5-15 mg/kg IV every 3 weeks
    • Toxicities: Hypertension, proteinuria, bowel perforation (2%), fistula
  • PARP inhibitors (Olaparib, Niraparib, Rucaparib):
    • Maintenance therapy after platinum response
    • Greatest benefit in BRCA1/2 mutation carriers (SOLO-1 trial: olaparib vs. placebo after first-line treatment in BRCA-mutated advanced ovarian cancer - 3-year PFS 60% vs 27%)

B. Management of Germ Cell Tumors

  • BEP chemotherapy (Bleomycin + Etoposide + Cisplatin) x 3-4 cycles - standard for malignant GCT
  • Fertility preservation is possible and usually achievable - unilateral salpingo-oophorectomy + staging + chemotherapy
  • Dysgerminoma: Highly radiosensitive and highly chemosensitive; excellent prognosis even for advanced disease
  • Yolk sac tumor: AFP monitoring for recurrence

C. Management of Recurrent Disease

Platinum SensitivityDefinitionTreatment
Platinum-refractoryProgression while on platinumNon-platinum agents (topotecan, gemcitabine); clinical trial
Platinum-resistantProgression within 6 monthsNon-platinum ± bevacizumab; consider clinical trial
Platinum-sensitiveRecurrence >6 monthsPlatinum + paclitaxel ± bevacizumab ± PLD; consider secondary debulking if >12 months interval and complete clinical response; maintenance PARP inhibitor
DESKTOP3 trial: Secondary cytoreduction + chemotherapy vs. chemotherapy alone for platinum-sensitive recurrence (>6 months interval) showed survival benefit when strict entry criteria met. - Schwartz's Principles of Surgery

D. Role of Radiation Therapy

  • Limited role in ovarian cancer
  • Whole-abdominal radiation: High morbidity (30% bowel obstruction); largely abandoned
  • May be used for palliative purposes in localized recurrence

E. Surveillance After Treatment

  • Clinical examination + CA-125 every 3 months x 2 years, then every 6 months x 3 years
  • CT scan when clinically indicated or CA-125 rising
  • BRCA testing of all patients with high-grade serous carcinoma

SUMMARY TABLE: Key Points for Exam

FeatureSerous CaMucinous CaDysgerminomaGranulosa Cell
% of malignant75-80%5%Most common GCTMost common SCST
MarkerCA-125CA-125, CEALDH, PLAPInhibin, AMH
MolecularTP53 (HG), KRAS/BRAF (LG)KRASIsochromosome 12pFOXL2 mutation
HistologyPapillae, psammoma bodiesGlands, mucinLarge cells, fibrous septaCall-Exner bodies
Special featuresFallopian tube originGI metastasis excludedBilateral 10-15%; chemo sensitiveLate recurrence; estrogen

CONCLUSION

Ovarian tumors represent the most diverse neoplasms in human pathology. Benign tumors (80% of all) are predominantly epithelial cystadenomas and germ cell teratomas. Malignant ovarian cancer - dominated by high-grade serous carcinoma - carries high mortality owing to silent early disease and advanced stage at diagnosis. The 2014 revised FIGO staging provides prognostic stratification with critical substages for IC, IIIA1, and the IVA/IVB distinction. Management centers on maximal surgical cytoreduction followed by platinum-taxane chemotherapy, with targeted agents (bevacizumab, PARP inhibitors) in selected patients. Early detection remains the unmet need in ovarian oncology.
Sources:
This is a shared conversation. Sign in to Orris to start your own chat.